SCHEDULE: William P. Scully Discloses 9.8% Stake in Prothena

William P. Scully has filed an amended Schedule 13G, disclosing a beneficial ownership of 9.8% of Prothena Corp Public Ltd Co's Ordinary Shares.

Summary

• William P. Scully beneficially owns 5,281,846 Ordinary Shares of Prothena Corp Public Ltd Co.
• This ownership represents approximately 9.8% of the issuer's total outstanding Ordinary Shares.
• The shares are held through various entities, including 80,000 shares by Manatee Equity Fund LLC, 683,000 shares in Scully's IRA, 42,000 shares in his spouse's IRA, 10,000 shares by his spouse, 23,000 shares in an IRA under investment management, 68,000 shares by a trust, 4,335,846 shares by various grantor retained annuity trusts, and 40,000 shares by another trust.
• Scully holds sole voting and dispositive power over 763,000 shares.
• Scully holds shared voting and dispositive power over 4,518,846 shares.
• The event requiring this filing occurred on September 30, 2025, with the statement filed on November 12, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a nearly 10% beneficial ownership stake by William P. Scully suggests strong investor confidence in Prothena Corp Public Ltd Co. While a Schedule 13G is a mandatory disclosure and not an operational update, a substantial stake by an individual can be interpreted positively by the market.

Positives

• A significant beneficial ownership stake of 9.8% by William P. Scully indicates strong conviction in Prothena Corp Public Ltd Co.
• The diverse holding structure across various trusts and personal accounts suggests a long-term investment strategy by a key individual.

Risks

• No specific risks are mentioned in this Schedule 13G filing, as it primarily concerns beneficial ownership disclosure rather than operational or financial risks.

Future Outlook

NA

Industry Context

This filing indicates a significant individual investor's confidence in Prothena, a biotechnology company. Large stakes by individuals or institutions can sometimes signal potential activist interest or simply strong belief in the company's long-term prospects, which is common in the biotech sector given its high-risk, high-reward nature.

Comparison to Industry Standards

• A 9.8% stake is a substantial position for an individual investor in a publicly traded company, often exceeding typical institutional fund allocations for a single individual.
• Such a concentration of ownership by an individual can be compared to significant founder stakes or early investor positions in growth-stage biotech firms, where conviction in specific drug pipelines or technological platforms drives large investments.

Stakeholder Impact

• Shareholders: May view the significant stake as a vote of confidence, potentially influencing stock price positively.
• Management: Awareness of a large individual shareholder may influence strategic decisions or communication.

Next Steps

• William P. Scully will continue to file amendments to Schedule 13G if there are material changes (1% or more) to his beneficial ownership or if his ownership drops below 5%.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership, not an operational or financial report. While a significant stake by an individual investor can be seen as a positive signal of confidence, it does not provide new fundamental information about the company's performance or future prospects to warrant a 'buy' or 'sell' recommendation solely based on this filing. Investors should 'hold' and consider this information in conjunction with Prothena's financial results and strategic updates.

Keywords

Prothena Corp, William P. Scully, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investor, Shareholder Stake, SEC Filing, G72800108